KNSA has been the topic of a number of other reports. BidaskClub upgraded shares of Kiniksa Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, February 5th. Goldman Sachs Group upgraded shares of Kiniksa Pharmaceuticals from a neutral rating to a buy rating and upped their target price for the stock from $16.00 to $18.00 in a research note on Friday, December 6th. Finally, Zacks Investment Research upgraded shares of Kiniksa Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, February 5th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Kiniksa Pharmaceuticals presently has an average rating of Buy and a consensus price target of $21.75.
KNSA stock traded down $0.93 during mid-day trading on Thursday, reaching $17.33. The company had a trading volume of 232,951 shares, compared to its average volume of 244,655. The company has a market capitalization of $970.24 million, a PE ratio of -5.22 and a beta of -1.06. The firm has a 50 day moving average of $14.48 and a 200 day moving average of $10.48. Kiniksa Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $21.50.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Further Reading: How Investors Can Profit from Options Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.